Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

被引：0
|
作者：
Rugo, H. S. [1 ]
Quek, R. [2 ]
Ettl, J. [3 ]
Hurvitz, S. A. [4 ]
Bhattacharyya, H. [2 ]
Hannah, A. L. [5 ]
Litton, J. K. [6 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[2] Pfizer Inc, Hlth Econ, San Francisco, CA USA
[3] Tech Univ Munich, Obs Gyn, Munich, Germany
[4] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA
[5] Pfizer Inc, Oncol, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT)
    Furlanetto, Jenny
    Moebus, Volker
    Schneeweiss, Andreas
    Rhiem, Kerstin
    Tesch, Hans
    Blohmer, Jens-Uwe
    Luebbe, Kristina
    Untch, Michael
    Salat, Christoph
    Huober, Jens
    Klare, Peter
    Schmutzler, Rita
    Couch, Fergus J.
    Lederer, Bianca
    Gerber, Bernd
    Zahm, Dirk-Michael
    Bauerfeind, Ingo
    Nekljudova, Valentina
    Hanusch, Claus
    Jackisch, Christian
    Link, Theresa
    Loibl, Sibylle
    Fasching, Peter A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 22 - 22
  • [22] Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)
    Furlanetto, Jenny
    Mobus, Volker
    Schneeweiss, Andreas
    Rhiem, Kerstin
    Tesch, Hans
    Blohmer, Jens-Uwe
    Lubbe, Kristina
    Untch, Michael
    Salat, Christoph
    Huober, Jens
    Klare, Peter
    Schmutzler, Rita
    Couch, Fergus J.
    Lederer, Bianca
    Gerber, Bernd
    Zahm, Dirk-Michael
    Bauerfeind, Ingo
    Nekljudova, Valentina
    Hanusch, Claus
    Jackisch, Christian
    Link, Theresa
    Loibl, Sibylle
    Fasching, Peter A.
    CANCER RESEARCH, 2020, 80 (04)
  • [23] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    Litton, J. K.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Goncalves, A.
    Diab, S.
    Woodward, N.
    Goodwin, A.
    Yerushalmi, R.
    Roch, H.
    Im, Y-H
    Eiermann, W.
    Quek, R. G. W.
    Usari, T.
    Lanzalone, S.
    Czibere, A.
    Blum, J. L.
    Martin, M.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2020, 31 (11) : 1526 - 1535
  • [24] EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD
    Robson, Mark E.
    Ruddy, Kathryn Jean
    Im, Seock-Ah
    Senkus-Konefka, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne Caroline
    Bannister, Wendy
    Goessl, Carsten Dietrich
    Degboe, Arnold
    Hettle, Robert
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    CANCER RESEARCH, 2018, 78 (13)
  • [26] OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice
    Delaloge, S.
    Conte, P. F.
    Im, S-A.
    Senkus-Konefka, E.
    Xu, B.
    Domchek, S. M.
    Masuda, N.
    Li, W.
    Tung, N.
    Armstrong, A.
    Wu, W.
    Goessl, C.
    Runswick, S.
    Robson, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC)
    Robson, M.
    Ruddy, K. J.
    Im, S-A.
    Senkus-Konefka, E.
    Xu, B.
    Domchek, S. M.
    Masuda, N.
    Delaloge, S.
    Li, W.
    Tung, N.
    Armstrong, A.
    Wu, W.
    Goessl, C.
    Degboe, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2-) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation
    Litton, Jennifer K.
    Laird, A. Douglas
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri
    Im, Young-Hyuck
    Goodwin, Annabel
    Blum, Joanne L.
    Eiermann, Wolfgang
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Albacker, Lee A.
    Frampton, Garrett M.
    Mina, Lida A.
    CANCER RESEARCH, 2020, 80 (16)
  • [29] A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)
    Litton, J.
    Symmans, F.
    Gogineni, K.
    Saltzman, M.
    Telli, M. L.
    Usha, L.
    Chakrabarti, J.
    Tudor, I. C.
    Quek, R. G.
    Czibere, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)
    Litton, J.
    Symmans, F.
    Gogineni, K.
    Saltzman, M.
    Telli, M. L.
    Usha, L.
    Chakrabarti, J.
    Tudor, I. C.
    Quek, R. G. W.
    Czibere, A.
    BREAST, 2019, 44 : S73 - S74
12345